BNC 210
Alternative Names: BNC-210; IW 2143Latest Information Update: 03 Dec 2025
At a glance
- Originator Bionomics
- Developer Bionomics; EmpathBio
- Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Small molecules
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Agitation; Post-traumatic stress disorders
- Suspended Anxiety disorders
- No development reported Depressive disorders
Most Recent Events
- 03 Dec 2025 Suspended - Phase-I for Anxiety disorders (In adults, In the elderly, In volunteers) in Australia (PO) prior to December 2025
- 03 Dec 2025 Suspended - Phase-I for Anxiety disorders (In volunteers) in France (PO) prior to December 2025
- 03 Dec 2025 Suspended - Phase-I for Anxiety disorders (In volunteers) in USA (PO) prior to December 2025